NEW YORK, August 1, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Investors' Reports announced new research reports highlighting Quest Diagnostics Incorporated (NYSE: DGX), PerkinElmer, Inc. (NYSE: PKI), PAREXEL International Corporation (NASDAQ: PRXL), Covance Inc. (NYSE: CVD), and ICON plc (NASDAQ: ICLR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Quest Diagnostics Incorporated Research Report
On July 18, 2013, Quest Diagnostics Incorporated (Quest Diagnostics) reported its Q2 2013 financial results. Q2 2013 adjusted income from continuing operations came in at $164 million, or $1.06 per diluted share, compared to $185 million, or $1.15 per diluted share, in Q2 2012. Q2 2013 revenues from continuing operations were $1.8 billion, down 3.3% YoY. Commenting on the results, Steve Rusckowski, President and CEO of Quest Diagnostics, said, "As expected, revenues and earnings improved from first quarter levels, but were down versus the prior year. We saw continued revenue softness in the second quarter compared to the prior year due to lower healthcare utilization and reductions in reimbursement." He added, "We lowered our full-year revenue guidance to reflect softer healthcare utilization." For full-year 2013, the Company now expects revenues to be down 1% to 2% YoY, compared to its previous guidance of approximating full-year 2012 level. The Full Research Report on Quest Diagnostics Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-30/DGX]
PerkinElmer, Inc. Research Report
On July 26, 2013, PerkinElmer, Inc. (PerkinElmer) announced that its Board of Directors has declared a regular quarterly dividend of $0.07 per share of common stock. PerkinElmer reported that the dividends will be payable on November 8, 2013, to shareholders of record at the close of business on October 18, 2013. The Full Research Report on PerkinElmer, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-30/PKI]
PAREXEL International Corporation Research Report
On July 10, 2013, PAREXEL International Corporation (PAREXEL) announced that it will present its Q4 FY 2013 and full-year FY 2013 financial results on August 7, 2013, after the close of the stock market. The Company will host a conference call and a live webcast on August 8, 2013 at 10:00 a.m. ET to discuss the results. The Full Research Report on PAREXEL International Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-30/PRXL]
Covance Inc. Research Report
On July 29, 2013, Covance Inc. (Covance) announced that its central laboratory services once again ranked first in an independent global survey of physician investigators participating in clinical trials, the Clinical Trial Investigator Satisfaction and Central Laboratory Performance survey. Covance informed that the survey was conducted in June and July 2013 by the Life Science Strategy Group, and in the survey, 47% of the study participants named Covance's central laboratory services as their most preferred central laboratory, with investigators citing Covance more than twice as often the nearest competitor. Further, investigators also reported having the best overall relationship with the Company, rating it 8.4 on a scale of 1 to 10. "This study demonstrates that investigators around the world continue to recognize and value Covance's services and benefit from our decades of experience and extensive testing capabilities," said Jon Koch, Corporate Vice President and Global General Manager of Central Laboratory Services at Covance. The Full Research Report on Covance Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-30/CVD]
ICON plc Research Report
On July 25, 2013, ICON plc (ICON) reported its Q2 2013 financial results. Q2 2013 net revenue increased 20.7% YoY to $334.2 million. Net income for Q2 2013, excluding restructuring charges, was $26.5 million, or $0.43 per diluted share, compared with $12.9 million, or $0.21 per diluted share in Q2 2012. Commenting on the results, the Company's CEO Ciaran Murray said, "I am happy that Q2 was another strong quarter for ICON. We reported revenue growth of 21% year on year and operating margins of 9.3%. We have continued to book satisfactory levels of new business and our trailing twelve month book to bill now stands at 1.3. Consequently we are raising our revenue guidance to the range of $1.3-$1.32 billion and our EPS guidance to the range of $1.54-$1.64 for the financial year 2013." The Full Research Report on ICON plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-30/ICLR]
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
|SOURCE Investors' Reports|
Copyright©2012 PR Newswire.
All rights reserved